97 related articles for article (PubMed ID: 573520)
1. [Humoral reactions in BALC/c mice with sarcomatous Moloney-induced tumor].
Yakimenko LV; Vetrova EP; Kaminskaya LP; Berdova AG; Umansky YA
Vopr Onkol; 1979; 25(9):46-50. PubMed ID: 573520
[TBL] [Abstract][Full Text] [Related]
2. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
3. Role of accessory cells in the induction of a secondary cytotoxic response to Moloney murine sarcoma virus-induced tumors.
Biasi G; Saggin L; Dazzi F; De Rossi A; Collavo D
J Immunol; 1983 Mar; 130(3):1447-50. PubMed ID: 6185589
[TBL] [Abstract][Full Text] [Related]
4. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
Harada M; Pearson G; Redmon L; Winters E; Kasuga S
J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
[TBL] [Abstract][Full Text] [Related]
5. Senescent loss of resistance to murine sarcoma virus (Moloney) in the mouse.
Pazmiño NH; Yuhas JM
Cancer Res; 1973 Nov; 33(11):2668-72. PubMed ID: 4748428
[No Abstract] [Full Text] [Related]
6. T cell tolerance in moloney-murine leukemia virus (M-MuLV) carrier mice: low cytotoxic T lymphocyte precursor frequency and absence of suppressor T cells in carrier mice with Moloney-murine sarcoma (M-MSV)-induced tumors.
Collavo D; Ronchese F; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1982 Feb; 128(2):774-9. PubMed ID: 6459385
[No Abstract] [Full Text] [Related]
7. Suppression of Moloney sarcoma virus immunity following sensitization with attenuated virus.
Wood GW
Cancer Res; 1976 Dec; 36(12):4552-7. PubMed ID: 1000500
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppression by spleen cells from Moloney leukemia. III. Evidence for a suppressor cell that is not the leukemic, virus-producing cell.
Cerny J; Grinwich KD; Stiller RA
J Immunol; 1977 Sep; 119(3):1097-101. PubMed ID: 330747
[TBL] [Abstract][Full Text] [Related]
9. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes.
Flyer DC; Burakoff SJ; Faller DV
J Immunol; 1985 Oct; 135(4):2287-92. PubMed ID: 2411792
[TBL] [Abstract][Full Text] [Related]
10. Blocking of cell-mediated immunity to Moloney murine sarcoma virus-transformed cells by lactate dehydrogenase virus-antibody complex.
McDonald TL
J Natl Cancer Inst; 1983 Mar; 70(3):493-7. PubMed ID: 6572738
[TBL] [Abstract][Full Text] [Related]
11. Augmented immunogenicity of tumor cell membranes produced by infection with influenza virus as compared to Moloney sarcoma virus.
Takeichi N; Austin FC; Oikawa T; Boone CW
Cancer Res; 1978 Dec; 38(12):4580-4. PubMed ID: 214226
[TBL] [Abstract][Full Text] [Related]
12. IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: the involvement of T and B lymphocytes as effector cells.
Lamon EW; Whitten HD; Skurzak HM; Andersson B; Lidin B
J Immunol; 1975 Nov; 115(5):1288-94. PubMed ID: 1080777
[TBL] [Abstract][Full Text] [Related]
13. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
14. Protection by immune spleen cells against challenge with Moloney sarcoma virus. Effect of stage of donor response.
Pollack S; Nelson K
Transplantation; 1973 May; 15(5):510-3. PubMed ID: 4710486
[No Abstract] [Full Text] [Related]
15. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of immune sera against transplantable Moloney virus-induced sarcoma and lymphoma.
Pearson GR; Redmon LW; Bass LR
Cancer Res; 1973 Jan; 33(1):171-8. PubMed ID: 4734119
[No Abstract] [Full Text] [Related]
17. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
Powell TJ; Spann R; Nguyenduc M; Lamon EW
J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cell-mediated immunologic reactivity to Moloney Murine sarcoma virus-induced tumors. III. Further characterization of tumor-specific serum blocking factors.
Halliday WJ; Koppi TA; McKenzie IF
J Natl Cancer Inst; 1982 Oct; 69(4):939-44. PubMed ID: 6750199
[TBL] [Abstract][Full Text] [Related]
19. Studies on the possibility of induction of anti-H-2 alloreactive cytotoxic antibodies by syngeneic immunization.
Opolski A; Radzikowski C
Arch Immunol Ther Exp (Warsz); 1984; 32(5):621-30. PubMed ID: 6085470
[TBL] [Abstract][Full Text] [Related]
20. Application of antisera to interferon in studying oncogenic viruses.
Inglot AD; Oleszak E
Arch Immunol Ther Exp (Warsz); 1978; 26(1-6):529-36. PubMed ID: 219809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
